Residents in eastern Congo cling to hope as a new Ebola treatment trial begins
Summary
A new medical trial began in early July in eastern Congo to test two experimental treatments for the Bundibugyo strain of the Ebola virus. The outbreak has infected over 1,400 people and caused 438 deaths, and the trial aims to see if these treatments help patients survive.Key Facts
- The Ebola outbreak is centered in eastern Congo’s Ituri province, particularly in Bunia.
- The virus strain causing this outbreak is called Bundibugyo, which is less common than other Ebola strains.
- There are currently no approved treatments or vaccines specific to the Bundibugyo strain.
- The World Health Organization (WHO) supports a trial testing remdesivir, an experimental antibody called MBP134, or a combination of both.
- The first participant was enrolled in the trial, which will monitor survival for 28 days after treatment starts.
- The trial is a partnership involving Congo’s national research institute, Oxford University, the Institute of Tropical Medicine in Antwerp, and other health organizations.
- The study will first treat confirmed Ebola patients in hospitals, later expanding to healthcare workers and people at high risk.
- Researchers expect the trial to last between three and six months, depending on how the outbreak develops.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
